Biocon Approval From Drugs Controller General Of India
- All
- News
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon, Mylan get DGCA nod for breast cancer drug
Biocon Ltd said on Tuesday it has won approval from the Drug Controller General of India (DGCA) for marketing a generic version of Roche's Herceptin, used in breast cancer treatment.
-
Biocon gets approval to market anti-psoriasis drug
Biotechnology major Biocon today said it has received approval from Drug Controller General of India (DCGI) to market its product 'Itolizumab', used in the treatment of psoriasis.
-
Biocon Soars Nearly 10% On Receiving Nod For Covid-19 Drug
Biocon Share: Biocon received approval from the Drugs Controller General of India to market its novel biologic drug Itolizumab for treating patients having Covid-19 complications.
-
Biocon, Mylan get DGCA nod for breast cancer drug
Biocon Ltd said on Tuesday it has won approval from the Drug Controller General of India (DGCA) for marketing a generic version of Roche's Herceptin, used in breast cancer treatment.
-
Biocon gets approval to market anti-psoriasis drug
Biotechnology major Biocon today said it has received approval from Drug Controller General of India (DCGI) to market its product 'Itolizumab', used in the treatment of psoriasis.
